COMPANY PROFILE

Fortis Therapeutics

Explore full profile

Developing precision therapies for cancer patients

San Diego, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Fortis Therapeutics

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, focusing on the development of antibody-drug conjugate therapies targeting CD46 proteins. These therapies are designed for the treatment of late-stage multiple myeloma and prostate cancer, among other indications. The company operates within the Community of Innovation in San Diego, leveraging cutting-edge science and technology to advance cancer treatment. Fortis Therapeutics' business model revolves around the research and development of precision therapies that selectively target tumor cells while sparing normal tissues, thereby enhancing treatment efficacy and safety. The company generates revenue through the development and potential commercialization of its proprietary therapies. Fortis serves the healthcare sector, specifically targeting patients with advanced cancer stages who require innovative treatment options. The company's approach is grounded in the understanding that CD46 is upregulated in tumor cells, making it an ideal target for antibody-drug conjugates. By focusing on this specific protein, Fortis aims to improve outcomes for patients with resistant forms of cancer.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: San Diego, United States
Employees: 2
Open positions: None listed
Dealroom signal: 26.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2021	$40M	$160M	Avalon Ventures · Vivo Capital · Osage University Partners · Myeloma Investment Fund	—
SPINOUT✓Other financing	Jan 2016	$0	—	Harvard University	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Fortis Therapeutics website traffic

Latest recorded traffic for Fortis Therapeutics is 2.9K monthly website visits, up 192.9% over the last three months. Fortis Therapeutics's team grew 0% over the past year.

Latest monthly visits2.9K 3-month web change+192.9% 1-year team growth0%

Monthly website visitsSep 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GBGuangdong Maijinjia BiotechnologyInnovative nucleic acid drug technologies for gene-specific protein upregulation, addressing high unmet medical needs	Guangzhou, China	Operational	—	$2.8M	$11M
INInnoRNAProprietary LNP platform for effective mRNA delivery, enabling advanced nucleic acid therapeutics	Shenzhen, China	Operational
7676bioDegradation by design 76Bio aims to develop transformational therapies for patients with life-threatening disease by pioneering the next generation of	New York City, United States	Operational
BBBridGene BiosciencesBiotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules	San Jose, United States	Operational
RBReplicate BioscienceDeveloping next-gen self-replicating RNA treatments for infectious diseases, oncology, and autoimmune disorders	San Diego, United States	Operational
OBOutpace BioRevolutionizing cell therapy with protein design, Outpace reprograms immune cells to make better decisions inside patients, enhancing cell therapy persistence and overcoming biology barriers to cancer treatment	Seattle, United States	Operational
ABAvenge BioFocusing cell generated immunotherapies to eradicate solid tumors	Foxborough, United States	Operational
MTMonte Rosa TherapeuticsDeveloping next-generation small molecule protein degraders to treat cancer and beyond	Boston, United States	Operational